Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04429087 · ClinicalTrials.gov registry record · Phase 1
A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
A Phase 1 study of Patients With Small Cell Lung Carcinoma and Other Neoplasms, sponsored by Boehringer Ingelheim.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 300
- Enrollment target
- 12
- Study locations
NCT04429087 is a Phase 1 study of Patients With Small Cell Lung Carcinoma and Other Neoplasms that is actively recruiting participants, run by Boehringer Ingelheim. The registered enrollment target is 300 participants. The trial reports 12 study locations across 5 states.
The verdict
NCT04429087, a Phase 1 study of Patients With Small Cell Lung Carcinoma and Other Neoplasms, is actively recruiting participants, sponsored by Boehringer Ingelheim.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 300 participants
- Enrollment target
- 12
- Study locations
Study Summary
This study is open to adults with small cell lung cancer and other neuroendocrine cancers that are positive for the tumour marker delta-like 3 (DLL3). The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find out the highest dose of BI 764532 and the best treatment schedule that people can tolerate. BI 764532 is an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. In this study, BI 764532 is given to people for the first time. That means no clinical data are available for BI 764532. Participants get BI 764532 either weekly or once every 3 weeks. If there is benefit for the participants and if they can tolerate it, the treatment is given for a maximum of 3 years. During this time, participants visit the study site about 20 times depending on the response to the treatment. Doctors record any unwanted effects and regularly check the general health of the participants.
Conditions Studied
Interventions
- DRUG BI 764532 - parenteral 1
- DRUG BI 764532 - parenteral 2
Study Locations (12)
Other
- Universitätsklinikum Köln (AöR) - Cologne
- Technische Universität Dresden - Dresden
- Universitätsklinikum Würzburg AÖR - Würzburg
- National Cancer Center Hospital East - Chiba, Kashiwa
- Hospital del Mar - Barcelona
- Hospital Universitari Vall D Hebron - Barcelona
- Clínica Universidad de Navarra - Pamplona
- Hospital Clinico Universitario De Valencia - Valencia
Georgia
- Winship Cancer Institute - Atlanta
Maryland
- University of Maryland School of Medicine - Baltimore
Missouri
- Washington University School of Medicine - St Louis
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2020-07-29 |
| Est. Completion | 2027-02-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04429087
The ClinicalTrials.gov registry entry for NCT04429087 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Patients With Small Cell Lung Carcinoma and Other Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which BI 764532 - parenteral 1 is the first listed.
NCT04429087 reports 12 study locations spanning 5 distinct geographic areas - top geographies include Other, Georgia, Maryland.
Frequently Asked Questions
What is clinical trial NCT04429087 about?
NCT04429087 is a clinical study titled "A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3". This study is open to adults with small cell lung cancer and other neuroendocrine cancers that are positive for the tumour marker delta-like 3 (DLL3). The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this stud...
What is the current status of trial NCT04429087?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 300 participants. The study started on 2020-07-29. Estimated completion is 2027-02-15.
What conditions does trial NCT04429087 study?
This clinical trial studies the following conditions: Patients With Small Cell Lung Carcinoma and Other Neoplasms.
What interventions are being tested in trial NCT04429087?
The interventions under investigation include: BI 764532 - parenteral 1 (DRUG), BI 764532 - parenteral 2 (DRUG).
Who is sponsoring clinical trial NCT04429087?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04429087 being conducted?
This trial has 12 study locations across Georgia, Maryland, Missouri, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.